%0 Journal Article %T Current Status and Progress in Molecular Imaging of Non-small Cell Lung £¿Cancer for Molecular Targeted EGFR-TKI Treatment Sensitivity and £¿Treatment Tolerance Prediction %A Dong DAI %A Wengui XU %A Qi WANG %A Xiaofeng LI %A Yanjia ZHU %J Öйú·Î°©ÔÓÖ¾ %D 2017 %R : 110.3779/j.issn.1009-3419.2017.12.10 %X More than 80% of lung cancer is non-small cell lung cancer (NSCLC), and the epidermal growth factor receptor (EGFR)-mediated signaling pathway is closely related to the occurrence and development of NSCLC. Small molecule EGFR-tyrosine kinase inhibitors (EGFR-TKI) targeting EGFR have been used in the clinical treatment of NSCLC, and positron emission tomography/computed tomgraphy (PET/CT) imaging can noninvasively monitor the expression and mutation status of EGFR in patients with NSCLC. 18F-FDG PET/CT imaging has predictive value for the activation of EGFR mutation and EGFR-TKI treatment efficacy, and in vivo can be directly observed drugs and systemic tumor targeting EGFR combined with the specific circumstances, by PET/CT imaging before and after treatment, to achieve dynamic monitoring, guide the therapy before treatment and treatment of sensitive population screening process, to achieve NSCLC EGFR-TKI precise treatment is essential. %K Lung neoplasms %K EGFR %K Targeted therapy %K PET/CT %K Molecular imaging %U http://www.lungca.org/index.php?journal=01&page=article&op=view&path%5B%5D=10.3779%2Fj.issn.1009-3419.2017.12.10